[PDF] Top 20 Calidad del aire : Monitoreo y modelado de contaminantes atmosféricos. Efectos en la salud pública
Has 10000 "Calidad del aire : Monitoreo y modelado de contaminantes atmosféricos. Efectos en la salud pública" found on our website. Below are the top 20 most common "Calidad del aire : Monitoreo y modelado de contaminantes atmosféricos. Efectos en la salud pública".
Considerations for payers in managing hormone receptor-positive advanced breast cancer
... efficacy, potential impact on QOL of patients, and more importantly, cost associated with therapy and with overall management. In addition to the pharmacotherapy-related factors described herein, patient medical history, ... See full document
7
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
... Clinical trials are currently investigating the safety and efficacy of three CDK4/6 inhibitors, palbociclib, abemaci- clib, and LEE011, for the treatment of HR+ HER2– ABC [25]. The compound with more mature clinical ... See full document
9
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
... of HER2 blockade and ER inhibition targets the actual escape mechanism evolved due to the cross-talk between the two driver pathways. Limited clinical data exist on the significance of alternating driver mechanisms in ... See full document
10
Exceptional Response to AKT inhibition in breast cancer patients with germline PTEN mutations
... with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 ... See full document
37
<p>Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer</p>
... with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) and compare the ef fi cacy of different CDKi ... See full document
10
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
... postmenopausal patients who had an Eastern Cooperative Oncology Group (ECOG) performance status 0−1 and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1 [6]) or ... See full document
39
A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
... Honestly, there are several limitations in the present meta- analysis, and it should be cautious when interpreting the results. First, different combination strategies, treatment regimens, drug doses, and patient ... See full document
11
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
... hormone receptor-positive mBC patients who had progressed on endocrine therapy and already received multiple systemic therapies (average of three prior systemic ... See full document
11
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
... locally advanced or metastatic HR+/HER2+ breast ...HER2-positive advanced or metastatic breast cancer previously treated with chemotherapy and trastuzu- ... See full document
14
Comparative study of neoadjuvant chemotherapy in hormone receptor positive and negative locally advanced breast carcinoma
... Oestrogen receptor was first identified in the ...oestrogen receptor modulators) or by blocking conversion of androgens to estrogens, forms the mainstay of endocrine therapy for carcinoma breast ... See full document
18
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
... Abstract: Breast cancers that overexpress human epidermal growth factor receptor-2 (HER2-positive [HER2+]) tend to be biologically aggressive and associated with a poor prognosis, even those that ... See full document
18
Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor–positive advanced breast cancer
... factor receptor 1/2 genes derived greater benefit with everolimus compared with the overall popula- tion, whereas patients with genetic alterations in at least two of these genes still benefited from the addition ... See full document
5
Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer
... 25. Novartis Pharmaceuticals. Everolimus in Combination With Exemes- tane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast ... See full document
110
Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study
... early breast cancer, data on the influence of HR status on trastuzumab treatment benefits in advanced HER2-positive breast cancer are ... See full document
9
Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis
... Sixteen articles (14 RCTs) published between 2000 and 2017, consisting of a total number of 6,602 participants with ABC were included in this NMA. The median age of participants across studies ranged from 60.2 to 72.6. ... See full document
10
Metformin increases survival in hormone receptor positive, HER2 positive breast cancer patients with diabetes
... of hormone receptor-positive, HER2-positive breast cancer by suppressing the AKT/mTOR signaling ...insulin receptor, and IGF-I receptor all act through the same ... See full document
26
Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer
... progesterone receptor (PR) measurements are currently used for both clinical diagnosis to classify BC patients and as a guide to endocrine therapy ...to hormone therapy is ...a positive prognostic ... See full document
104
Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer
... IHC breast biomarkers such as ER, PR and HER2 as well as Ki67, may have a similar prognostic value when compared to Oncotype Dx in ...of cancer— uncontrolled proliferation and genome instability ... See full document
41
Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
... estrogen receptor-positive patients had longer PFS and OS when receiving hormone therapy plus bevacizumab versus patients receiving only bevacizumab (HR ... See full document
6
Genetic polymorphisms in the cyclooxygenase 2 gene, use of nonsteroidal anti inflammatory drugs, and breast cancer risk
... and breast cancer risk might be explained by interin- dividual differences in COX-2 gene expression or be limited to certain subtypes of breast ...overall breast cancer risk or risk for ... See full document
15
Related subjects